Os Therapies Incorporated (OSTX) Stock Price, Quote & News

Company Profile

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate (ADC) silicone dioxide linker technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS...

Industry: Biotechnology

Sector: Healthcare

Phone: 410 297 7793

Website: ostherapies.com

Address:

115 Pullman Crossing Road, Suite 103, Grasonville, United States

TeaBaggerVance Jan. 28 at 2:19 PM

$OSTX Everyone, including the institutional investors, are all waiting for this filing. To some, nothing is real about this company until that happens, and a smaller pool of investors won’t believe in their success until the BLA is accepted (30-60 days). My experience tells me that the floodgates will be raised about 2 feet when they file and another 20 feet when it’s accepted.

1 · Reply

edelhead Jan. 28 at 1:27 PM

$OSTX Interesting story this morning about a $120 million donation just made to UC Davis School of Veternarian Medicine. This donation was made by the Weill family in thanks for their dog's prior treatment there. This makes be realize that the spinoff shares we'll be getting in a few months from OSTX is one of many reasons why this stock is ridiculously undervalued! A lot of money is spent each year by dog owners for canine medical treatments!

0 · Reply

Juhanialainen Jan. 28 at 9:59 AM

$OSTX Two months from now the FDA will decide if the process goes as planned to the PDUFA or do they want extra data or revised documents. If the BLA is accepted as it is, expect growing share price up to the PDUFA date. If it's a hit, the stock price will 10X easily by the year's end.

0 · Reply

Manonfire8 Jan. 27 at 8:28 PM

$OSTX added 1700 more shares here; will add more post filing

0 · Reply

Jetphoenix Jan. 27 at 7:30 PM

$OSTX My hunch is announcement comes Friday AH and it will include BLA + closing of its warrants offer raising $7.5M (100% participation already agreed)... we will have weekend momentum going into next Monday

2 · Reply

somaopp Jan. 27 at 5:35 PM

$OSTX as of now it seems to be trading for bla next week??

0 · Reply

RajivD Jan. 27 at 3:13 PM

$OSTX BLA confirmation should be next week. If it comes sooner well and good but nothing to worry about if it doesn't come this week. It will be quickly followed by the warrant conversions then the BLA acceptance within 2 months and the spin off. So a few catalysts to spike the SP and we will alternate that with 15-25% retracements on low volume weeks. If final Approval comes through we will 8x-10x by final quarter. Nice comfortable play if you're holding shares.

2 · Reply

NoFooling Jan. 27 at 3:04 PM

$OSTX What is the expected impact on PPS when the filing of the BLA is announced?

2 · Reply

Retired2010 Jan. 27 at 2:53 PM

$OSTX 2026 should be very good with this stock. 2000 shares at 1.76

1 · Reply

Juhanialainen Jan. 27 at 2:31 PM

$OSTX Maybe tomorrow? The price has been incredibly flat for quite some time. The BLA will ring many bells, so we should see some action in few days.

0 · Reply

OS Therapies Bone Cancer Trial Data Strengthens FDA Case

Jan 15, 2026, 7:00 AM EST - 13 days ago

OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jan 14, 2026, 7:00 AM EST - 14 days ago

OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary

Jan 12, 2026, 8:01 AM EST - 16 days ago

OS Therapies Enters into Warrant Inducement Agreements

Jan 5, 2026, 7:40 AM EST - 23 days ago

OS Therapies Provides First Half 2026 Corporate Outlook

Dec 15, 2025, 6:00 AM EST - 6 weeks ago

OS Therapies Announces Successful Type C Meeting with US FDA Regarding Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 9, 2025, 7:40 AM EST - 7 weeks ago

OS Therapies Announces Successful pre-Marketing Authorisation Application Meeting with UK MHRA Regarding the Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Dec 5, 2025, 8:01 AM EST - 7 weeks ago

OS Therapies Announces FDA PDUFA Waiver & EMA Grants Union Marketing Authorisation Eligibility

Nov 25, 2025, 9:21 AM EST - 2 months ago

OS Therapies Receives Non-Proprietary Name 'daznelimgene lisbac' for OST-HER2 from World Health Organization

Nov 21, 2025, 4:15 PM EST - 2 months ago

Stonegate Capital Partners Updates Coverage on OS Therapies Inc. (OSTX) 3Q25

Nov 20, 2025, 7:40 AM EST - 2 months ago

OS Therapies to Spinoff OS Animal Health into Standalone Public Company

Nov 17, 2025, 6:00 AM EST - 2 months ago

OS Therapies Reports Third Quarter 2025 Financial Results and Provides Business Update

Oct 22, 2025, 9:15 AM EDT - 3 months ago

OS Therapies Announces Overall and Event Free Survival Key Subgroup Data for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 17, 2025, 9:15 AM EDT - 3 months ago

OS Therapies Granted Final Type C Meeting by U.S. FDA and pre-MAA Meeting by U.K. MHRA for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Oct 10, 2025, 6:00 AM EDT - 3 months ago

OS Therapies Announces Statistically Significant Positive Final 2-Year Overall Survival Data from Phase 2b Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully-Resected, Pulmonary Metastatic Osteosarcoma

Oct 9, 2025, 7:40 AM EDT - 3 months ago

OS Therapies Provides Positive EMA Regulatory Update Following Positive Rapporteur Meeting

Oct 7, 2025, 11:50 AM EDT - 4 months ago

OS Therapies to Participate in Fall 2025 Conferences and Events

Sep 30, 2025, 7:40 AM EDT - 4 months ago

OS Therapies Provides OST-HER2 UK MHRA and US FDA Osteosarcoma Regulatory Update

Sep 19, 2025, 7:40 AM EDT - 4 months ago

OS Therapies to Participate in Spotlight Panel at BioFuture 2025 October 13 11:00am EDT

Sep 12, 2025, 7:40 AM EDT - 4 months ago

OS Therapies Announces Last Patient Enrolled in OST-504 (previously ADXS-504) Phase 1b Prostate Cancer Clinical Trial Completes Last Visit

Sep 8, 2025, 5:12 PM EDT - 5 months ago

Stonegate Capital Partners Initiates Coverage on OS Therapies Inc. (OSTX)

Sep 3, 2025, 7:40 AM EDT - 5 months ago

OS Therapies to Participate in Upcoming Investor Conferences in September 2025

Sep 2, 2025, 7:40 AM EDT - 5 months ago

OS Therapies Provides OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma Program Update Following FDA End of Phase 2 Meeting

Sep 2, 2025, 6:00 AM EDT - 5 months ago

OS Therapies Completes Exercise Inducement and Exchange Offer for All Remaining Outstanding Warrants Issued in Connection with December 2024 Financing

Aug 27, 2025, 4:01 PM EDT - 5 months ago

OS Therapies to Provide OST-HER2 Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma FDA End of Phase 2 Meeting Update on Tuesday, September 2, 2025

Aug 25, 2025, 9:51 PM EDT - 5 months ago

OS Therapies Terminates Equity Line of Credit

Aug 19, 2025, 6:00 AM EDT - 5 months ago

OS Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 14, 2025, 5:44 PM EDT - 5 months ago

OS Therapies to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 19th, 2025

Aug 7, 2025, 9:00 AM EDT - 6 months ago

OS Therapies Announces Statistically Significant Positive Interim 2-Year Overall Survival Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Aug 7, 2025, 6:00 AM EDT - 6 months ago

OS Therapies Receives Positive Feedback from UK MHRA Scientific Advice Meeting and Submits Innovative Licensing and Access Pathway (ILAP) Request for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jul 14, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Closes $4.2 Million in Warrant Exercise Inducement and Exchange Offer

Jul 10, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Provides Clinical & Global Regulatory Updates

Jul 3, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Granted End of Phase 2 Meeting by US FDA for OST-HER2 Program in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

Jun 30, 2025, 6:00 AM EDT - 7 months ago

OS Therapies Presents Statistically Significantly Positive 1-Year Event Free Survival, Overall Survival and Safety Clinical Data Updates for OST-HER2 at the MIB Agents Factor Osteosarcoma Conference

Jun 24, 2025, 7:40 AM EDT - 7 months ago

OS Therapies Receives Positive FDA Meeting Feedback on Regulatory Pathway for Accelerated Approval of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 23, 2025, 8:29 PM EDT - 7 months ago

OS Therapies Announces Warrant Exercise Inducement & Exchange Offer

Jun 10, 2025, 7:40 AM EDT - 8 months ago

OS Therapies Partners with EVERSANA for the U.S. Commercialization of OST-HER2 in Recurrent, Fully Resected, Pediatric Lung Metastatic Osteosarcoma

Jun 6, 2025, 7:30 AM EDT - 8 months ago

OS Therapies Submits Request for Regenerative Medicine Advanced Therapy (RMAT) Designation to U.S. FDA for OST-HER2 in the Prevention of Metastases in Recurrent, Fully-Resected, Lung Metastatic Pediatric Osteosarcoma

May 16, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Reports First Quarter 2025 Financial Results and Provides Business Update

May 15, 2025, 6:00 AM EDT - 9 months ago

OS Therapies Forms Subsidiary OS Animal Health to Commercialize OST-HER2 for Canine Osteosarcoma

May 7, 2025, 8:45 AM EDT - 9 months ago

OS Therapies Announces Issuance of U.S. Patent #12,239,738 Protecting Commercial Manufacturing Market Exclusivity for OST-HER2 in Rare Pediatric Cancer Osteosarcoma and Full Listeria Cancer Immunotherapy Platform into 2040

May 2, 2025, 9:32 AM EDT - 9 months ago

Emmy-Winning Series Debuts Trailer for "Shelter Me: The Cancer Pioneers" Offering A Hopeful Look at Breakthrough Cancer Therapies

Apr 22, 2025, 7:40 AM EDT - 10 months ago

OS Therapies FDA Meeting Request Granted

Apr 10, 2025, 7:42 AM EDT - 10 months ago

OS Therapies Announces Positive Data for OST-HER2 in the Treatment of Unresected Osteosarcoma in Dogs Opening the Potential for Use as Front-Line Therapy in Humans

Apr 9, 2025, 7:40 AM EDT - 10 months ago

OS Therapies Completes Acquisition of Advaxis Immunotherapies Clinical, Pre-clinical and IP Assets from Ayala Pharmaceuticals

Apr 7, 2025, 6:00 AM EDT - 10 months ago

OS Therapies Requests Meeting with FDA to Gain Agreement on Surrogate Endpoint(s) for Breakthrough Therapy Designation & Accelerated Approval of OST-HER2 in the Prevention of Recurrence of Fully Resected, Lung Metastatic Osteosarcoma

Apr 2, 2025, 7:40 AM EDT - 10 months ago

OS Therapies to Host Analyst Day at NYSE on April 7, 2025

Mar 31, 2025, 4:30 PM EDT - 10 months ago

OS Therapies Reports Full Year 2024 Financial Results and Provides Business Update

Mar 31, 2025, 7:40 AM EDT - 10 months ago

OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate OST-HER2 for Human Osteosarcoma

TeaBaggerVance Jan. 28 at 2:19 PM

1 · Reply

edelhead Jan. 28 at 1:27 PM

0 · Reply

Juhanialainen Jan. 28 at 9:59 AM

0 · Reply

Manonfire8 Jan. 27 at 8:28 PM

$OSTX added 1700 more shares here; will add more post filing

0 · Reply

Jetphoenix Jan. 27 at 7:30 PM

2 · Reply

somaopp Jan. 27 at 5:35 PM

$OSTX as of now it seems to be trading for bla next week??

0 · Reply

RajivD Jan. 27 at 3:13 PM

2 · Reply

NoFooling Jan. 27 at 3:04 PM

$OSTX What is the expected impact on PPS when the filing of the BLA is announced?

2 · Reply

Retired2010 Jan. 27 at 2:53 PM

$OSTX 2026 should be very good with this stock. 2000 shares at 1.76

1 · Reply

Juhanialainen Jan. 27 at 2:31 PM

$OSTX Maybe tomorrow? The price has been incredibly flat for quite some time. The BLA will ring many bells, so we should see some action in few days.

0 · Reply

TeaBaggerVance Jan. 27 at 12:50 AM

$OSTX The odds are very high that tomorrow could be the BLAy.

1 · Reply

Bengalbear Jan. 26 at 5:44 PM

$OSTX How confident are you that BLA will be granted? And whats the predictions for sp?

2 · Reply

Juhanialainen Jan. 26 at 5:13 PM

$OSTX Ok, let's ride this BLA out!

0 · Reply

RajivD Jan. 26 at 4:50 PM

$OSTX this is boring, cmon shorties, atleast try to make us sell.🤣

0 · Reply

edelhead Jan. 26 at 1:17 PM

$OSTX Good morning. I have been kicking the tires for a while on OSTX, and have concluded, based on my own due diligence, that this stock is an absolute steal at these levels! I am now officially "long" on this stock and look forward to a very exciting year ahead!!

1 · Reply

TeaBaggerVance Jan. 26 at 4:07 AM

$OSTX Most of us are aware of the process towards and potential value of a PRV which is what makes the upcoming BLA filing such a meaningful catalyst. I’m not sure if very many people realize that if we get Accelerated Approval for OST-HER2 (July/August Target) we can immediately start generating revenue from this medication while our confirmatory phase 3 study is taking place. By October we could have millions in revenue and another $200 million coming our way from the sale of the PRV. These warrants we’re dealing with very well could be the last signs of dilution we see until they force the brand new ones to cash out once our stock price is over $9 for 20 consecutive days. We are setup for major success here, all you have to do is what’s arguably the hardest thing to do, NOTHING. 📈📈📈📈📈

0 · Reply

TeaBaggerVance Jan. 25 at 10:44 PM

$OSTX For what it’s worth, here’s what ChatGPT has to say about the timing of our BLA submission this week.

0 · Reply

My_Lai_1968 Jan. 25 at 4:48 PM

$OSTX Does OSTX still provide critical infant care for unwed teenage mothers requiring angioplasties and tracheotomies due to unprotected sex? I would strongly appreciate only sincere and insightful responses and will likely quickly admonish any derogatory and tasteless remarks.

1 · Reply

LIT_L7 Jan. 25 at 3:53 PM

$OSTX "end of January to file with the FDA the BLA..." 5 more days and Boom? Maybe 6 days if they are working Saturday. Yeah, right... Cheers-

0 · Reply

nik4 Jan. 25 at 2:36 AM

$OSTX 📌 What a BLA Is A BLA is the formal regulatory filing with the U.S. Food and Drug Administration (FDA) that requests permission to market and sell a biologic drug (in OSTX’s case, OST-HER2) in the United States. It’s not just paperwork — it packages all clinical trial, manufacturing, and safety data into a submission that the FDA must review before approval can be granted. Biotech stocks often trade heavily around regulatory milestones. A BLA submission puts the company on a defined path toward approval

0 · Reply

TeaBaggerVance Jan. 25 at 2:27 AM

$OSTX is approaching a major inflection point. The upcoming BLA filing is a concrete regulatory milestone that should re-rate the stock immediately, as it reduces uncertainty and signals execution on a critical FDA pathway. Historically, biotech names often see a valuation reset upon filing alone, as risk compresses and institutional interest increases. But the real catalyst may come as soon as 30 days later — when the FDA decides whether to ACCEPT the BLA for review (30-60 days after the company files). Acceptance is a powerful validation event and could trigger a much larger upside move, as it confirms the application is complete and officially under review. Filing = near-term price expansion. Acceptance = potential breakout leg much higher as it immediately increases the probability of getting a PRV. This setup is shaping up to be a two-stage catalyst window — and the clock is ticking. 📈📈📈📈📈📈📈📈📈📈📈📈📈📈

0 · Reply

iholdTNXPbutIhateSeth Jan. 23 at 7:07 PM

$OSTX if not today, someday, this stock will pump and I’ll be ready to sell and move on.

0 · Reply

Market Cap	51.77M
Revenue (ttm)	0.00
Net Income (ttm)	-8.88M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	348,000
Avg Vol	514,368
Day's Range	N/A - N/A
Shares Out	35.21M
Stochastic %K	17%
Beta	-3.79
Analysts	Strong Sell
Price Target	$12.75